Statement: Although there is a much higher percentage of patients with Enterocolitis in the secondary trial than in cohort 1 of the primary trial, no robust comparisons can be made due to the significant differences in cohort sizes.
Primary_evidence: Adverse Events 1:   Total: 59/199 (29.65%)   Anaemia 7/199 (3.52%)   Thrombocytopenia 2/199 (1.01%)   Acute myocardial infarction 0/199 (0.00%)   Atrial fibrillation 1/199 (0.50%)   Cardiac arrest 1/199 (0.50%)   Cardiac failure 1/199 (0.50%)   Cardiopulmonary failure 1/199 (0.50%)   Left ventricular failure 1/199 (0.50%)   Supraventricular tachycardia 0/199 (0.00%)   Ventricular tachycardia 1/199 (0.50%) Adverse Events 2:   Total: 16/36 (44.44%)   Anaemia 2/36 (5.56%)   Thrombocytopenia 1/36 (2.78%)   Acute myocardial infarction 1/36 (2.78%)   Atrial fibrillation 0/36 (0.00%)   Cardiac arrest 0/36 (0.00%)   Cardiac failure 0/36 (0.00%)   Cardiopulmonary failure 0/36 (0.00%)   Left ventricular failure 0/36 (0.00%)   Supraventricular tachycardia 1/36 (2.78%)   Ventricular tachycardia 0/36 (0.00%)
Secondary_evidence: Adverse Events 1:   Total: 6/8 (75.00%)   Thrombocytopenia 1/8 (12.50%)   Hypertension 1/8 (12.50%)   Hepatotoxicity 3/8 (37.50%)   Pancreatectomy * 1/8 (12.50%)